IPO - Acurx Pharmaceuticals, Inc.

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925032184

Filing Summary: Acurx Pharmaceuticals, Inc. filed a registration statement on Form S-1 with the SEC to offer up to 8,399,700 shares of its common stock. The offering includes shares issuable upon the exercise of series F warrants and placement agent warrants. The estimated effective date for this offering is not specified, but sales are expected to commence soon after the effective date. The company is classified as an 'emerging growth company' and a 'smaller reporting company', with a focus on developing antibiotics for difficult-to-treat infections. The shares will be sold by certain stockholders, with proceeds from sales going entirely to them, while Acurx will not receive any proceeds from the resale but may receive proceeds from warrant exercises. The registration includes discussions of the risks involved with investing in the company's securities, including ongoing compliance with Nasdaq listing requirements. Recent developments highlight upcoming compliance deadlines and offerings that occurred in early 2025.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009147

Filing Summary: Acurx Pharmaceuticals, Inc. is requesting the U.S. Securities and Exchange Commission for acceleration of the effective date of its Registration Statement on Form S-1, which is designated as File No. 333-284627. The company seeks to have the registration become effective on February 6, 2025, at 4:01 p.m. (Washington, D.C. time), or as soon thereafter as practicable. This request is made in accordance with Rule 461 of Regulation C under the Securities Act of 1933, as amended. The correspondence indicates the involvement of legal counsel from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and provides contact details for further inquiries.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000067

Filing Summary: Acurx Pharmaceuticals, Inc. filed Form S-1 registration statement with the SEC for the proposed public offering of 2,610,841 shares of common stock. This includes 2,463,058 shares issuable upon exercise of series E warrants at an exercise price of $0.90 per share and 147,783 shares issuable upon exercise of placement agent warrants with an exercise price of $1.2688 per share. The selling stockholders will receive proceeds from these sales, while Acurx will incur expenses related to the offering. The common stock is listed on The Nasdaq Capital Market under the symbol 'ACXP.' The last reported price of the stock was $0.759 per share on January 30, 2025. Acurx is classified as an emerging growth company and is subject to reduced public reporting requirements. Risks associated with the offering are discussed in the prospectus, indicating that investing in the company's stock is speculative and entails significant risk.

Document Link: View Document